Skip to main content

Table 3 Characteristics of patients included in analyses of attrition and mortality at initiation of ART

From: Determinants of time to antiretroviral treatment initiation and subsequent mortality on treatment in a cohort in rural northern Malawi

Total—n

432

Registered within KHDSS—n (%)

398 (92)

Route of HIV testing—n (%)

CRH

203 (47)

HIV serosurvey

181 (42)

Missing

48 (11)

Sex—n (%)

Male

189 (44)

Female

243 (56)

Age—n (%)

15–34

162 (38)

≥35

270 (63)

Median age—years

38.0

Weight—kg

Median (IQR)

52.9 (46.8–58.4)

Missing—n (%)

12 (3)

Median BMI

20.1

Year of ART initiation—n (%)

2008

150 (35)

2009

106 (25)

2010

117 (27)

2011

59 (14)

WHO stage—n (%)

1

49 (11)

2

134 (31)

3

203 (47)

4

46 (11)

CD4 count—n (%) cells/μL

≤250

285 (66)

251–350 

33 (8)

351–500 

14 (3)

>500

9 (2)

Missing

91 (21)

Median CD4 count—cells/μL (IQR)

Overall

156 (77–227)

By route of HIV testing

CRH

139 (62–222)

HIV serosurvey

167 (108–227)

Missing

169 (69–244)

Starting Regimen—n (%)

d4T-3TC-NVPa

431 (99.8)

TDF-3TC-EFVb

1 (0.2)

Clinical Details—n (%)

Weight loss >10 %

107 (25)

Oral candidiasis

74 (17)

Severe bacterial infection

72 (17)

Unexplained fever >1 month

32 (7)

Wasting syndrome

14 (3)

Pulmonary tuberculosis

12 (3)

Kaposi’s sarcoma

10 (2)

Oesophageal candidiasis

9 (2)

Extrapulmonary tuberculosis

5 (1)

  1. aStavudine, lamivudine and nevirapine
  2. bTenofovir disoproxil fumarate, lamivudine and efavirenz